Cynthia Ma, MD
Enriched profileProfessor of Medicine, Division of Oncology, Section of Breast Oncology · Washington University School of Medicine
Cynthia Ma is Professor of Medicine, Division of Oncology, Section of Breast Oncology at Washington University School of Medicine. OpenAlex indexes 654 publications with 16,463 citations (h-index 65); ClinicalTrials.gov lists 27 registered studies with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Cynthia Ma, MD, is Professor of Medicine, Division of Oncology, Section of Breast Oncology at Washington University School of Medicine, Siteman Cancer Center. The public record shows 654 publications with 16,463 citations (h-index 65), centered on Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Cancer Genomics and Diagnostics. It also documents an investigator role on 27 registered clinical trials, industry payments reported by 21 companies, 3 NIH-funded awards (2017–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Breast Cancer Treatment Studies
- 27 registered trials on ClinicalTrials.gov
- Open Payments reporting from 21 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 39 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 190.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 27 registered studies on ClinicalTrials.gov. The most recent:
- Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients
Sponsor: Washington University School of Medicine
- Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer
Sponsor: Washington University School of Medicine
Industry payments
Updated 18 Oct 2026
21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20258 payments
- AstraZeneca UK LimitedProgram year20254 payments
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
40%PD-1 inhibitor37.6%Pembrolizumab100%Part B, office-administered≥11 patientsAromatase Inhibitor1.4%Letrozole48%Anastrozole34%Exemestane18%Part D≥16 patients+ 3 more classes in this area
Metabolism & gastrointestinal
40%Other antiemetics35.6%Fosaprepitant100%Part B, office-administered≥12 patientsSerotonin-3 Receptor Antagonist4.1%Palonosetron hcl92%Ondansetron Odt5%Ondansetron Hcl3%Part D + Part B<11 patients+ 2 more classes in this area
Musculoskeletal
11.4%RANK Ligand Inhibitor11.4%Denosumab100%Part B, office-administered≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
3 NIH research awards on record, funded 2017–2026 per NIH RePORTER. The latest:
- Washington University Co-Clinical Imaging Research Resource
Washington University
FY2026$645,323U24CA209837 - Regulation of resistance to CDK4/6 inhibitor in breast cancer
George Washington University
FY2026$633,959R01CA275904
Congress activity
Updated 18 Oct 2026
147 congress contributions (2012–2025) across AACR, ASCO per OpenAlex. The most recent:
- Abstract 2809: Targeting the LINC00355-MENIN interaction with CDK4/6 inhibitors to reduce proliferation in late relapse breast cancer
AACR Annual Meeting
AACR2025Co-author - Abstract 5333: CDK4/6 inhibitors in patients with bone-only metastatic breast cancer, the role of immune microenvironment
AACR Annual Meeting
AACR2025Co-author - Abstract 5339: Single cell analysis enables tracking the evolution of resistance to CDK4/6 inhibitors in ER+ breast cancer
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The Next Frontier in Quantitative Co-Clinical Imaging to Advance Functional Precision Oncology.
Clinical cancer research
Article2026 - Spatial Mapping of the Precancer-to-Cancer Transition in Breast and Prostate.
Cancer discovery
Article2026 - Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.
Clinical cancer research
Clinical Trial2026 - Author Correction: O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer.
Nature communications
Erratum2026
Most-cited works
by citation count (OpenAlex)- 01CDK4/6 inhibition triggers anti-tumour immunityArticle1,506 citations2017
- 02Activating HER2 Mutations in HER2 Gene Amplification Negative Breast CancerArticle868 citations2012
- 03
- 04
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
siteman.washu.edu/doctor/ma-cynthia
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →siteman.washu.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →siteman.washu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →siteman.washu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →siteman.washu.edu ↗
Editorial & leadership roles
journal and society appointments- Member
AACR Breast Cancer Research Grants Scientific Review Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →siteman.washu.edu ↗ - Member
American Society of Clinical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →siteman.washu.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →siteman.washu.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →icts.wustl.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →icts.wustl.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →icts.wustl.edu ↗
Secondary affiliations
appointments beyond the home institution- Co-leader
Breast Cancer Focus Group, Siteman Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →siteman.washu.edu ↗ - Clinical Director
Breast Cancer Program, Washington University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →siteman.washu.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
John Dipersio, MD
Washington University School of Medicine
Douglas Mann, MD
Washington University School of Medicine
Nancy Bartlett, MD
Washington University School of Medicine
Geoffrey Uy, MD
Washington University School of Medicine
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Norman Wolmark, MD
University of Pittsburgh
Hope Rugo, MD
City of Hope